Table 1.
Patient characteristics.
| Demographic Characteristics | Results, All | Results, AITL 2 | Results, cHL 3 |
|---|---|---|---|
| Patients, n | 12 | 5 (42%) | 7 (58%) |
| Age at diagnosis, y, median (range) | 56 (19–63) | 58 (55–63) | 25 (19–62) |
| Age at ASCT 1, y, median (range) | 56 (19–64) | 58 (55–64) | 25 (19–62) |
| Male/female ratio | 3:1 | 2:3 | 7:0 |
| Histopathology | |||
| CD30+ lymphocytes (histopathology at diagnosis), %, median (range) | 85 (1–100) | 5 (1–10) | 95 (80–100) |
| Stage at diagnosis (Ann Arbor), n (%) | |||
| I | 1 (8%) | 0 (0%) | 1 (14%) |
| II | 2 (17%) | 0 (0%) | 2 (29%) |
| III | 4 (33%) | 2 (40%) | 2 (29%) |
| IV | 5 (42%) | 3 (60%) | 2 (29%) |
| International Prognostic Index (IPI) at diagnosis, n (%) | |||
| 0 | 0 (0%) | NA | |
| 1 | 0 (0%) | NA | |
| 2 | 2 (40%) | NA | |
| 3 | 3 (60%) | NA | |
| Clinical manifestations at diagnosis, n (%) | |||
| B-symptoms | 8 (67%) | 4 (80%) | 4 (57%) |
| Extranodal involvement | 5 (42%) | 2 (40%) | 3 (43%) |
| Bone marrow infiltration | 0 (0%) | 0 (0%) | 0 (0%) |
| Spleen | 2 (17%) | 2 (40%) | 0 (0%) |
| Mediastinum | 2 (17%) | 0 (0%) | 2 (29%) |
| Other | 3 (25%) | 2 (40%) | 1 (14%) |
| Time from Diagnosis to ASCT 1, m, median (range) | 8 (5–148) | 6 (5–7) | 25 (7–148) |
| Previous therapies | |||
| Prior lines of chemotherapy, median (range) | 2 (1–3) | 1 (1–2) | 3 (2–3) |
| First-line therapies | |||
| ABVD 5, n (%) | 3 (25%) | 0 (0%) | 3 (43%) 3 |
| BEACOPP 6, n (%) | 2 (17%) | 0 (0%) | 2 (29%) |
| CHOP 7, n (%) | 3 (25%) | 3 (60%) | 0 (0%) |
| Others, n (%) | 4 (33%) | 2 9 (40%) | 2 10 (29%) |
| Subsequent therapies | |||
| BEACOPP 6, n (%) | 1 (8%) | 0 (0%) | 1 (14%) |
| DHAP 4, n (%) | 4 (33%) | 0 (0%) | 4 (57%) |
| BV 8, n (%) | 1 (8%) | 0 (0%) | 1 (14%) |
| Radiotherapy, n (%) | 2 (17%) | 0 (0%) | 2 (29%) |
| Others 9, n (%) | 5 (42%) | 1 11 (20%) | 4 12 (57%) |
| Remission status before ASCT 1, n (%) | |||
| Complete remission (CR) | 8 (67%) | 3 (60%) | 5 (71%) |
| Partial remission (PR) | 4 (33%) | 2 (40%) | 2 (29%) |
1 Autologous stem cell transplant; 2 angioimmunoblastic T-cell lymphoma; 3 classical Hodgkin’s lymphoma; 4 dexamethasone, high-dose cytarabine, and cisplatin; 5 doxorubicin, bleomycin, vinblastine, and dacarbazine; 6 bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; 7 cyclophosphamide, doxorubicin, vincristine, and prednisone; 8 brentuximab vedotin; 9 A + CHP (brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone, n = 1), CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone n = 1); 10 BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, adriamycin, dacarbazin, and dexamethasone n = 1), Stanford V (mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone, n = 1); 11 A + CHP (brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone, n = 1); 12 DHAO (dexamethasone, high-dose cytarabine, and oxaliplatin n = 2), ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin, n = 1), IGEV (ifosfamide, gemcitabine, vinorelbine, and prednisone, n = 1).